TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04217551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.
Study: NCT00788645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD self care advice
Description: Information leaflets on COPD and thermometers to monitor the ambient temperature in the bedroom and living room
Study: NCT04217551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.
Study: NCT02910037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mNGS for pathogen detection
Description: This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
Study: NCT01185821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
Study: NCT00788645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD self care advice
Description: Information leaflets on COPD and thermometers to monitor the ambient temperature in the bedroom and living room

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poor weather forecast warning
Description: Interactive automated telephone service to contact patients prior to anticipated periods of poor weather
Study: NCT03429127

Intervention type: OTHER
Intervention: Normal saline
Description: Plasma osmolality, acid base status and electrolytes after application up to 2000 ml of normal saline during neurosurgical operation
Study: NCT01185821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
Study: NCT03802682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive apalutamide 240 mg as a whole tablets administered orally (Treatment A) or as a dispersed mixture in applesauce (Treatment B) under fasted condition.
Study: NCT03429127

Intervention type: OTHER
Intervention: Balanced fluid
Description: Plasma osmolality, acid base status and electrolytes after application of up to 2000 ml balanced fluids during neurosurgical operation
Study: NCT04703569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dressing with monolayer high compression elastic bandage
Description: The nurse will be apply the therapy high compression elastic bandage once a week, during 26 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing with Unna boot
Description: The nurse will be apply the therapy Unna Boot once a week, during 26 weeks.
Study: NCT00356642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW842470X
Description: GW842470X will be available as a yellow smooth water-in-oil cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW842470X
Description: GW842470X will be available as a yellow smooth water-in-oil cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW842470X
Description: GW842470X will be available as a yellow smooth water-in-oil cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW842470X
Description: GW842470X will be available as a yellow smooth water-in-oil cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.
Study: NCT04282005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metabolic/Bariatric surgery
Description: Patients will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle and Diet
Description: Patients will be provided with a lifestyle interventions including dietary counselling choosing between a Low-Calorie Diet or a Meal Replacement Diet.
Study: NCT02663739

Intervention type: DEVICE
Intervention: Zenith® TXD
Description: Zenith® TXD Dissection Stent Graft System for treatment of patients with aortic dissection of the descending thoracic aorta
Study: NCT02346188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Description: Tablet formulated from 30 mg ferrous fumarate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Description: Tablet formulated from 30 mg ferrous fumarate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc oxide
Description: Tablet formulated from 30 mg zinc oxide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc oxide
Description: Tablet formulated from 30 mg zinc oxide

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01160601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel / Carboplatin
Description: Patients will receive commercially available paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve \[AUC\] 6) on Day 1 of each 21 day cycle for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel / Carboplatin
Description: Patients will receive commercially available paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve \[AUC\] 6) on Day 1 of each 21 day cycle for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab
Description: Patients will receive 3 mg/kg bavituximab, administered weekly until progression or toxicity.
Study: NCT01109940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457A
Study: NCT03653390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EnhanceWellness for Disability (EW-D)
Description: Participants work one-on-one with the study Wellness Coach to identify health self-management problems, consider options, develop goals and an action plan, and make adjustments to that plan over time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Education
Description: Sessions will cover: (1) blood pressure management; (2) smoking cessation; (3) cancer screening; (4) regulation of blood glucose; (5) decreasing LDL cholesterol; (6) physical activity; (7) bone, joint, and muscle health; and (8) immunizations.
Study: NCT04844255

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: dietary salt
Description: 2 grams of dietary salt
Study: NCT01575795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180mg loading dose 180mg loading dose
Study: NCT03342950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Solution
Description: Topical Solution of Clonidine (0.01%) + Pentoxifylline (5%) in anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Topical Solution of anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
Study: NCT01592201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperdidone ER
Description: Form = osmotic release oral system, route = oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperdidone ER
Description: Form = osmotic release oral system, route = oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole, olanzapine and risperidone (Antipsychotics)
Description: Form = tablet, route = oral
Study: NCT04436276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive intramuscular (IM) injection of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive intramuscular (IM) injection of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive intramuscular (IM) injection of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive intramuscular (IM) injection of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
Study: NCT04436276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo.
Study: NCT01933841

Intervention type: DEVICE
Intervention: TOF-Watch SX
Description: As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.

Intervention type: DEVICE
Intervention: TOF-Watch SX
Description: As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.

Intervention type: DEVICE
Intervention: TOF-Watch SX
Description: As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.

Intervention type: DEVICE
Intervention: TOF-Watch SX
Description: As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.

Intervention type: PROCEDURE
Intervention: Notify the provider
Description: Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated Reversal Support team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio.

Intervention type: PROCEDURE
Intervention: Notify the provider
Description: Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated Reversal Support team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio.

Intervention type: PROCEDURE
Intervention: Notify the provider
Description: Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated Reversal Support team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio.

Intervention type: PROCEDURE
Intervention: Notify the provider
Description: Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated Reversal Support team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio.
Study: NCT02690194

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: The placebo group will wear headphones and listen to nature sounds.
Study: NCT03601962

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aqualief
Description: 400mg oral mucoadesive tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg Placebo oral mucoadesive tablets
Study: NCT02690194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buddhify Therapy
Description: The experimental group will complete a Buddhify relaxation therapy session, before their injection. This therapy consists of wearing headphones and listening to guided meditation instructions.
Study: NCT03568877

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metabolaid®
Description: 500 mg per day, in fasting conditions.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg per day, in fasting conditions.
Study: NCT01292655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024
Study: NCT03290950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: Cycle 1 ONLY: Daratumumab 16 mg/kg days 1, 8, 15, and 22, Cycle 2: Daratumumab 16mg/kg days 1, 8, 15, and 22; Cycles 3-6: Daratumumab 16mg/kg days 1 and 15, Cycles 7-8: Daratumumab 16mg/kg day 1; Daratumumab rate of infusion is per MSKCC guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: Cycle 1 ONLY: Daratumumab 16 mg/kg days 1, 8, 15, and 22, Cycle 2: Daratumumab 16mg/kg days 1, 8, 15, and 22; Cycles 3-6: Daratumumab 16mg/kg days 1 and 15, Cycles 7-8: Daratumumab 16mg/kg day 1; Daratumumab rate of infusion is per MSKCC guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 2 and 3; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16; Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 2 and 3; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16; Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Cycle 1 ONLY: Lenalidomide 25 mg/day, days 2-21 every 28 days; Cycles 2-8: Lenalidomide 25 mg/day, days 1-21 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Cycle 1 ONLY: Lenalidomide 25 mg/day, days 2-21 every 28 days; Cycles 2-8: Lenalidomide 25 mg/day, days 1-21 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 2, 3, 8, 9, 15, 16, Cycles 2: Dexamethasone 20mg/dose, days 1, 2, 8, 9, 15, 16 and 22; Cycles 3-4: Dexamethasone 20mg/dose, days 1,2,8,9,15 and 16, Cycles 5- 8: Dexamethasone 10mg/dose, days 1, 2, 8, 9, 15, and 16
Study: NCT03290950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 1, 2, 22; 40 mg/dose days 8 and 15, Cycles 2: Dexamethasone 40mg/dose, days 1, 8, 15; 20 mg/dose day 22, Cycles 3-4: Dexamethasone 40mg/dose, Days 1, 8 15, Cycles 5-8: Dexamethasone 20mg/dose, Days 1, 8, 15
Study: NCT02946801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Essential oils

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils without alcohol
Study: NCT02576353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl Sublingual Spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl Sublingual Spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl Sublingual Spray (FSS)
Study: NCT02946801

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sterile water
Study: NCT01564836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imatinib treatment discontinuing
Description: Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled
Study: NCT03992144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 Mg
Description: Amoxicillin 500mg an hour before tooth extraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole 400mg
Description: 400mg of metronidazole an hour before extraction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazol 400mg and amoxicillin 500mg
Description: 400mg metronidazole TDS, amoxicillin 500mg BD for 5 days after extraction
Study: NCT03163381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg,po,qd,medicine to disease progression.
Study: NCT00797693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol ( Cytotec) 200 microgram a tablet
Description: In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol ( Cytotec) 200 microgram a tablet
Description: In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.
Study: NCT04082208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow nasal cannula
Description: Administration of high flow nasal cannula during ERCP procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow nasal cannula
Description: Administration of low flow nasal cannula during ERCP procedure: standard care
Study: NCT03064490

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Neoadjuvant Pembrolizumab ( 3 cycles) administered concurrently with weekly Carboplatin and Paclitaxel and daily radiation therapy; followed by surgical resection and adjuvant Pembrolizumab ( 3 cycles)
Study: NCT02576353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl Sublingual Spray (FSS)
Study: NCT02115230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation + medical therapy
Description: Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
Study: NCT02848833

Intervention type: DRUG
Intervention: JARDIANCE 10mg
Description: T2DM with JARDIANCE 10mg

Intervention type: DRUG
Intervention: JARDIANCE 25mg
Description: MT2DM with JARDIANCE 25mgax
Study: NCT02576353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl Sublingual Spray (FSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: Fentanyl Citrate IV (FCIV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: Fentanyl Citrate IV (FCIV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: Fentanyl Citrate IV (FCIV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: Fentanyl Citrate IV (FCIV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: Fentanyl Citrate IV (FCIV)